114 related articles for article (PubMed ID: 38719260)
1. Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
Shi X
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719260
[TBL] [Abstract][Full Text] [Related]
2. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
3. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
5. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.
Han J; Lee WJ; Hur KY; Cho JH; Lee BW; Park CY
Diabetes Metab J; 2024 May; 48(3):418-428. PubMed ID: 38310883
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
Chang KC; Shao SC; Kuo S; Yang CY; Chen HY; Chan YY; Ou HT
Cardiovasc Diabetol; 2020 Oct; 19(1):172. PubMed ID: 33036617
[TBL] [Abstract][Full Text] [Related]
17. Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
Garg A; Kumar A
Curr Drug Saf; 2018; 13(3):165-170. PubMed ID: 29852875
[TBL] [Abstract][Full Text] [Related]
18. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
[TBL] [Abstract][Full Text] [Related]
19. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
